Ignite Creation Date:
2024-05-05 @ 5:35 PM
Last Modification Date:
2024-10-26 @ 9:33 AM
Study NCT ID:
NCT00483496
Status:
COMPLETED
Last Update Posted:
2017-12-22
First Post:
2007-06-06
Brief Title:
Evaluation of the Protection Activity of Microfine Titanium Dioxide Ti02 Pigmentary Ti02 and Bisoctrizole and Their Combinations in Voluntary Patients With Idiopathic Solar Urticaria SU
Sponsor:
Orfagen
Organization:
Orfagen
Study Overview
Official Title:
Evaluation of the Protection Activity of Microfine Ti02 Pigmentary Ti02 and Bisoctrizole and Their Combinations in Voluntary Patients With SU Phase II Photoprovocation Test
Status:
COMPLETED
Status Verified Date:
2017-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Commercially available external photoprotectors EP do not provide adequate protection against ultraviolet A UVA and visible wavelengths The proposed medicinal product V0096 CR formula RV3131A-MV1166 is a broad spectrum EP bsEP The rationale for the use of V0096 CR formula RV3131A-MV1166 in the proposed condition is based on its ability to broadly block the UVA radiations and visible light that are known to trigger solar urticaria SU
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None